Scarica l'app Stockscreener
423.24
1.60%
-6.90
Dopo l'orario di chiusura:
420.34
-2.90
-0.69%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$430.14
Aprire:
$424.44
Volume 24 ore:
1.06M
Relative Volume:
0.78
Capitalizzazione di mercato:
$107.66B
Reddito:
$12.07B
Utile/perdita netta:
$3.95B
Rapporto P/E:
27.60
EPS:
15.3349
Flusso di cassa netto:
$3.19B
1 W Prestazione:
-3.30%
1M Prestazione:
-2.27%
6M Prestazione:
+1.45%
1 anno Prestazione:
-15.94%
Intervallo 1D:
$419.71
$426.72
Intervallo di 1 settimana:
$419.71
$442.04
Portata 52W:
$362.50
$510.77
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight - GlobeNewswire Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Stock with Promising Technical Setup - ChartMill
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect - Yahoo Finance
Vertex Pharma stock (US92532F1003): Is cystic fibrosis dominance still enough for long-term upside? - AD HOC NEWS
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness - Yahoo Finance
Is Vertex Pharmaceuticals heading to $600? - MSN
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know - MSN
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Vanguard Group Inc. - MarketBeat
Vertex Pharma in pact with Halozyme for Hypercon drug delivery tech - MSN
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Vertex Pharmaceuticals Incorporated (VRTX) PT Nudged Higher as RBC Updates Biotech Sector Outlook - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by M&T Bank Corp - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by China Universal Asset Management Co. Ltd. - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Arizona State Retirement System - MarketBeat
Layoff Tracker: Tempero winding down following serious adverse event - BioSpace
Teacher Retirement System of Texas Decreases Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Evergreen Capital Management LLC Buys 2,304 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
B. Metzler seel. Sohn & Co. AG Buys 199,847 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc. (VRTX)Bullish Jim Cramer Endorsement Highlights Divergent Sentiment Amid Mixed Pipeline UpdatesAsset Sale - Xã Thanh Hà
Best Biotech Stocks To Watch TodayApril 22nd - MarketBeat
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $577 - Moomoo
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings (NASDAQ:VRTX) - Seeking Alpha
Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Caprock Group LLC - MarketBeat
VRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Jim Cramer on Vertex Pharmaceuticals: “I Wish I Had Bought It for the Charitable Trust a Long Time Ago” - Insider Monkey
Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $612 - Moomoo
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
SageGuard Financial Group LLC Makes New $3.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Jones Kertz & Associates Inc. Invests $1.82 Million in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Halozyme Therapeutics Partners with Vertex for Hypercon Technology - HarianBasis.co
Fierce Biotech Layoff Tracker 2026: Replimune reduces staff; Astellas shutters cell therapy site - Fierce Biotech
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Vertex Pharma stock (US92532F1003): Is the cystic fibrosis dominance now unlocking broader upside? - AD HOC NEWS
Vertex Pharma stock (US92532F1003): Is its cystic fibrosis dominance strong enough to unlock new ups - AD HOC NEWS
Zurcher Kantonalbank Zurich Cantonalbank Has $160.26 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Merit Financial Group LLC Buys 2,880 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
2 Under-the-Radar Biotech Stocks Worth Buying for the Long Term - The Motley Fool
Vertex Pharmaceuticals Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
GF Fund Management CO. LTD. Raises Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Stock Position Lifted by Asset Management One Co. Ltd. - MarketBeat
Morgan Stanley Lifts Vertex Pharmaceuticals (VRTX) PT on Updated Biopharma Models - Insider Monkey
Cramer's lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning round: Buy Vertex Pharmaceuticals - MSN
Lightning Round: Buy Vertex Pharmaceuticals - CNBC
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex (VRTX) director receives new deferred stock unit grant - Stock Titan
VRTX Stock Quote Price and Forecast - CNN
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.21%
0.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):